Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DAPAGLIFLOZIN AND SAXAGLIPTIN HYDROCHLORIDE vs ALESSE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Dapagliflozin is a sodium-glucose cotransporter 2 (SGLT2) inhibitor that blocks glucose reabsorption in the proximal renal tubule, reducing plasma glucose independent of insulin secretion. Saxagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that prolongs incretin hormone activity, increasing insulin release and decreasing glucagon secretion.
Combination of ethinyl estradiol and levonorgestrel suppresses gonadotropin-releasing hormone (Gn RH) secretion from the hypothalamus, inhibiting pituitary release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH), thereby preventing ovulation. Additionally, it thickens cervical mucus, impeding sperm penetration, and alters endometrial receptivity.
Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus
Prevention of pregnancy,Treatment of moderate acne vulgaris (in women ≥15 years who have achieved menarche and desire contraception),Contraception in women with heavy menstrual bleeding (off-label)
Oral: 1 tablet (dapagliflozin 5 mg / saxagliptin 5 mg) once daily, taken with or without food, in combination with metformin or other glucose-lowering agents.
One tablet (ethinyl estradiol 20 mcg, levonorgestrel 0.1 mg) orally once daily at the same time each day for 21 days, followed by 7 days of placebo. For initiation, start on the first day of menstrual period or first Sunday after onset of menses.
Dapagliflozin: Terminal half-life ~12.9 hours (supports once-daily dosing). Saxagliptin: Terminal half-life ~2.5 hours, but active metabolite 5-hydroxy saxagliptin has half-life ~3.1 hours (supports once-daily dosing due to prolonged DPP-4 inhibition).
Levonorgestrel: terminal half-life ~17-20 hours (range 11-25 hr). Ethinyl estradiol: biphasic; terminal half-life ~13-27 hours (mean ~17 hr). Clinical context: steady-state achieved within 5-7 days. The half-life supports once-daily dosing with at least 24-hour contraceptive coverage.
Dapagliflozin is primarily metabolized via glucuronidation by UGT1A9; saxagliptin is metabolized via CYP3A4/5 to an active metabolite.
Ethinyl estradiol is primarily metabolized by CYP3A4 and undergoes conjugation (glucuronidation and sulfation). Levonorgestrel is metabolized by CYP3A4 and reduction, with conjugation to glucuronide and sulfate conjugates.
Dapagliflozin: ~75% renal excretion (21% unchanged, 50% as major metabolite 3-O-glucuronide), ~21% fecal. Saxagliptin: ~75% renal excretion (12% unchanged, 22% as major metabolite 5-hydroxy saxagliptin, 41% as other metabolites), ~22% fecal.
Renal: ethinyl estradiol (UE2) and levonorgestrel (LNG) metabolites primarily excreted in urine (UE2: ~40% as sulfate and glucuronide conjugates; LNG: ~25% as glucuronides). Fecal/biliary: ~40% (UE2) and ~45% (LNG) eliminated in feces via bile. Unchanged drug excretion is negligible.
Dapagliflozin: ~91% bound primarily to albumin. Saxagliptin: Negligible (<10% bound).
Levonorgestrel: 97-99% bound to albumin and sex hormone-binding globulin (SHBG). Ethinyl estradiol: 98-99% bound, primarily to albumin (98.5%), with minor binding to SHBG. Free fractions: LNG ~1%, UE2 ~1.0-1.5%.
Dapagliflozin: Vd ~118 L (1.5 L/kg based on 70 kg, indicating extensive extravascular distribution). Saxagliptin: Vd ~71 L (1.0 L/kg based on 70 kg, indicating distribution into tissues).
Levonorgestrel: Vd ~1.8 L/kg (range 1.5-2.0 L/kg). Ethinyl estradiol: Vd ~2.5-3.5 L/kg (mean ~2.9 L/kg). Indicates extensive tissue distribution, including target organs (ovaries, endometrium, breast). Not clinically adjusted for obesity.
Dapagliflozin: Oral bioavailability ~78% (high, influenced by food). Saxagliptin: Oral bioavailability ~75% (high, not significantly affected by food).
Oral: levonorgestrel ~95-100% (highly bioavailable). Ethinyl estradiol ~45-55% (first-pass metabolism reduces bioavailability; interindividual variability due to gut wall and hepatic conjugation). Both are prodrugs requiring hydrolysis for activity.
e GFR ≥45 m L/min/1.73 m²: No dose adjustment. e GFR 30–44 m L/min/1.73 m²: Not recommended due to limited data for saxagliptin. e GFR <30 m L/min/1.73 m²: Contraindicated due to dapagliflozin; do not initiate, discontinue if e GFR falls below 30.
No specific GFR-based dose adjustments are recommended; however, use with caution in patients with renal impairment due to potential fluid retention and hypertension.
Child-Pugh Class A: No dose adjustment. Child-Pugh Class B: Not recommended for saxagliptin (limited data) and caution for dapagliflozin. Child-Pugh Class C: Contraindicated or not recommended.
Contraindicated in patients with severe hepatic disease (Child-Pugh class C) or active liver disease. In mild to moderate impairment (Child-Pugh A or B), use only if benefits outweigh risks; no specific dose reduction guidelines are available.
Not established. Safety and efficacy in pediatric patients (<18 years) have not been studied.
Approved for postmenarchal adolescents; same dosing as adults: one tablet orally once daily for 21 days followed by 7 days of placebo. No weight-based adjustments are recommended.
No specific dose adjustment; monitor renal function (e.g., e GFR) and volume status due to age-related decrease in renal function and increased risk of hypotension, dehydration, and acute kidney injury.
Not indicated for use in postmenopausal women; no specific geriatric dosing adjustments are necessary if used off-label, but consider increased risk of thrombotic events in older women.
There is no black box warning for this combination product.
Cigarette smoking increases the risk of serious cardiovascular events from combination oral contraceptive use. The risk increases with age, particularly in women over 35 years, and with heavy smoking (≥15 cigarettes per day). Women over 35 who smoke should not use this medication.
Pancreatitis,Heart failure,Hypoglycemia when used with insulin or insulin secretagogues,Acute kidney injury,Genital mycotic infections,Urinary tract infections,Hypotension,Ketoacidosis,Necrotizing fasciitis of the perineum (Fournier’s gangrene),Arthralgia,Bullous pemphigoid
Increased risk of thromboembolic disorders (venous and arterial),Cigarette smoking increases risk of cardiovascular events, especially in women over 35,Hepatic neoplasia (benign and malignant),Elevated blood pressure,Gallbladder disease,Carbohydrate and lipid metabolism effects,Headache/migraine,Depression,Uterine bleeding irregularities,Ocular lesions (e.g., retinal thrombosis),Carcinoma of the breast and reproductive organs (close monitoring in current or history of breast cancer)
History of serious hypersensitivity reaction to dapagliflozin, saxagliptin, or any component,Severe renal impairment (e GFR <30 m L/min/1.73 m²) or end-stage renal disease,Diabetic ketoacidosis,Type 1 diabetes mellitus
Breast cancer (current or history),Carcinoma of the endometrium or other estrogen-dependent neoplasia,Thrombophlebitis or thromboembolic disorders (current or history),Cerebrovascular or coronary artery disease (current or history),Valvular heart disease with complications,Severe hypertension,Diabetes with vascular involvement,Headaches with focal neurological symptoms (e.g., migraine with aura),Major surgery with prolonged immobilization,Known or suspected pregnancy,Active liver disease or impaired liver function,Undiagnosed abnormal uterine bleeding,Hypersensitivity to any component,Cigarette smoking in women over 35 years of age
No specific food restrictions; alcohol may increase hypoglycemia risk.
No specific food restrictions. Grapefruit juice may slightly increase ethinyl estradiol levels but not clinically significant. High-fat meals do not affect absorption. Avoid excessive alcohol as it may impair compliance.
Dapagliflozin is contraindicated in the second and third trimesters due to risk of fetal renal toxicity. Saxagliptin has limited human data; animal studies show no major malformations but potential for delayed ossification at high doses. First trimester: Use only if clearly needed; no well-controlled human studies. Second and third trimesters: Dapagliflozin not recommended; avoid.
Pregnancy category X. Use contraindicated in pregnancy. First trimester exposure associated with cardiovascular defects (e.g., VSD), neural tube defects, and cleft lip/palate. Second and third trimester exposure may cause fetal adrenal suppression, hepatic dysfunction, and virilization of female genitalia due to progestin component (levonorgestrel). Increased risk of ectopic pregnancy if conception occurs during use.
No data on excretion in human milk. Dapagliflozin is present in rat milk; saxagliptin is excreted in rat milk. M/P ratio unknown. Caution advised due to potential for adverse effects in nursing infant.
Excreted in breast milk. Levonorgestrel M/P ratio approximately 0.3–0.4. Small amounts of ethinyl estradiol present. May reduce milk production and quality due to estrogen component. Use only if benefit outweighs risk; consider alternative contraception. American Academy of Pediatrics considers it compatible with nursing.
No specific dose adjustments established for pregnancy. Dapagliflozin is not recommended in pregnancy; consider alternative therapy. Saxagliptin: dose adjustment not required based on pharmacokinetic changes; however, lack of data limits recommendation.
Contraindicated. No dose adjustments apply as drug must be discontinued immediately if pregnancy suspected or confirmed. Pharmacokinetic changes in pregnancy (increased clearance, volume of distribution) not relevant due to contraindication.
Monitor renal function before initiation and periodically; contraindicated if e GFR <45 m L/min/1.73 m². Assess volume status due to diuretic effect. Watch for pancreatitis and hypersensitivity. Adjust insulin or sulfonylurea doses to reduce hypoglycemia risk. Discontinue if pancreatitis suspected. T1DM is not an indication.
ALESSE is a combined oral contraceptive (COC) containing ethinyl estradiol (20 mcg) and levonorgestrel (100 mcg). It is indicated for contraception and treatment of acne vulgaris in women aged ≥14. Monitor for thromboembolic events, especially in smokers >35 years. Assess for contraindications including migraines with aura, hypertension, and history of DVT/PE. Advise use of backup contraception if a pill is missed. Start on first day of menses or first Sunday after onset. Check BP at baseline and annually. Counsel on increased risk of VTE, especially in first year.
Take once daily with or without food; swallow tablets whole.,Stay hydrated to prevent dehydration from increased urination.,Genital mycotic infections may occur; report any symptoms.,Severe joint pain possible; advise seeking medical attention.,Do not share insulin pens or needles.,Store medication at room temperature away from moisture and heat.
Take one pill daily at the same time each day, even if you do not have sex.,Missed pill instructions: if late by <12 hours, take it as soon as remembered and continue schedule. If >12 hours, take missed pill (even if means taking two in one day) and use backup contraception for 7 days.,Possible side effects: nausea, breast tenderness, headache, breakthrough bleeding, especially in first 3 months.,Seek emergency care for signs of blood clot: leg pain/swelling, sudden chest pain, shortness of breath, severe headache, vision changes.,Do not smoke while on ALESSE, especially if over age 35, as it increases risk of serious cardiovascular events.,Inform your healthcare provider of all medications and supplements you take, as some (e.g., rifampin, anticonvulsants, St. John's wort) may reduce effectiveness.
"Saxagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, enhances incretin levels leading to glucose-dependent insulin secretion, while Milnacipran, a serotonin-norepinephrine reuptake inhibitor (SNRI), may independently affect glucose homeostasis. Concurrent use could theoretically increase the risk of hypoglycemia due to additive effects on insulin secretion or glucose metabolism, although clinical data are limited. Patients should be monitored for signs of hypoglycemia, especially if also on other glucose-lowering agents."
"Tolazamide, a sulfonylurea, increases insulin secretion from pancreatic beta cells, while saxagliptin, a DPP-4 inhibitor, prolongs the action of incretin hormones (GLP-1 and GIP) to enhance glucose-dependent insulin release. When coadministered, the complementary mechanisms can lead to additive hypoglycemic effects, significantly increasing the risk of hypoglycemia, particularly in patients with renal impairment or those on irregular meal schedules."
"Saxagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, has been reported to potentially reduce the systemic exposure of theophylline, a xanthine bronchodilator, likely through the induction of cytochrome P450 (CYP) 1A2, the primary enzyme responsible for theophylline metabolism. This interaction may lead to subtherapeutic theophylline concentrations, resulting in decreased bronchodilator efficacy and potential exacerbation of respiratory symptoms, particularly in patients with asthma or chronic obstructive pulmonary disease. The effect appears to be modest but may be clinically relevant in patients requiring stable theophylline levels."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about DAPAGLIFLOZIN AND SAXAGLIPTIN HYDROCHLORIDE vs ALESSE, answered by our medical review team.
DAPAGLIFLOZIN AND SAXAGLIPTIN HYDROCHLORIDE is a DPP-4 Inhibitor that works by Dapagliflozin is a sodium-glucose cotransporter 2 (SGLT2) inhibitor that blocks glucose reabsorption in the proximal renal tubule, reducing plasma glucose independent of insulin secretion. Saxagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that prolongs incretin hormone activity, increasing insulin release and decreasing glucagon secretion.. ALESSE is a Estrogen/Progestin Combination Contraceptive that works by Combination of ethinyl estradiol and levonorgestrel suppresses gonadotropin-releasing hormone (Gn RH) secretion from the hypothalamus, inhibiting pituitary release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH), thereby preventing ovulation. Additionally, it thickens cervical mucus, impeding sperm penetration, and alters endometrial receptivity.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between DAPAGLIFLOZIN AND SAXAGLIPTIN HYDROCHLORIDE and ALESSE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of DAPAGLIFLOZIN AND SAXAGLIPTIN HYDROCHLORIDE is: Oral: 1 tablet (dapagliflozin 5 mg / saxagliptin 5 mg) once daily, taken with or without food, in combination with metformin or other glucose-lowering agents.. The standard adult dose of ALESSE is: One tablet (ethinyl estradiol 20 mcg, levonorgestrel 0.1 mg) orally once daily at the same time each day for 21 days, followed by 7 days of placebo. For initiation, start on the first day of menstrual period or first Sunday after onset of menses.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between DAPAGLIFLOZIN AND SAXAGLIPTIN HYDROCHLORIDE and ALESSE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. DAPAGLIFLOZIN AND SAXAGLIPTIN HYDROCHLORIDE is classified as Category A/B. Dapagliflozin is contraindicated in the second and third trimesters due to risk of fetal renal toxicity. Saxagliptin has limited human data; animal studies show no major malformati. ALESSE is classified as Category C. Pregnancy category X. Use contraindicated in pregnancy. First trimester exposure associated with cardiovascular defects (e.g., VSD), neural tube defects, and cleft lip/palate. Seco. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.